Marshall’s 2004 paper argues that people who are sick with “autoimmune” diseases possess a correctable defect in innate immunity brought about by a dysregulation of vitamin D, which allows slow-growing, mutated bacteria, known as L-form bacteria as well as biofilm bacteria, to proliferate. He also believes that a range of other chronic inflammatory diseases—which he terms “Th1 illnesses”– result from the same bacterial pathogenesis as sarcoidosis. Thus, in every Th1 disease, chronic bacterial forms directly interfere with vitamin D metabolism, causing the release of Th1 cytokines.
Marshall believes that patients with Th1 illness are capable of restoring innate immunity by using the ARB Benicar to activate the VDR, while at the same time avoiding exogenous sources of vitamin D—the kinds of vitamin D present in various foods and catalyzed by exposure to bright lights and sunlight. Along with the help of pulsed, low-dose antibiotics, the body’s immune system can then destroy L-form bacteria, causing a temporary change in a patient’s immunopathology. He argues that the release of cytokines and endotoxins generated by this reaction cause an increase in past or present Th1 symptoms. These concepts became the fundamental aspects of his treatment plan for Th1 illness, which his colleagues named the ‘Marshall Protocol’.
In several US Patent applications in 2006 Marshall contends that his protocol is a treatment or a method of prevention for a wide range of diseases,including at least 35 different autoimmune diseases including rheumatoid arthritis, multiple sclerosis,Type 1 diabetes and Hashimoto’s Thyroiditis. He also asserted in his patent applications that the treatment is also effective in a range of poorly understood illnesses such as chronic fatigue syndrome and gulf war syndrome, as well as several neurodegenerative diseases including Parkinson’s, Multiple Sclerosis, Autism Spectrum Disorder (ASD), Attention Deficit Disorder (ADD), Attention Deficit Hyperactivity Disorder (ADHD), Schizophrenia, Obsessive Compulsive Disorder (OCD), Dysthymia, Bipolar Disorders, Epilepsy, and Dementia.
Simple explanation of the Marshall Protocol
The Marshall Protocol was developed by Professor Trevor Marshall, Ph.D in 2002 to treat certain diseases that involve Th1 immune system dysfunction.
Prof. Marshall’s papers describe how numerous Th1 diseases such as sarcoidosis, Lyme disease, chronic fatigue syndrome, fibromyalgia, lupus and rheumatoid arthritis (among others) are caused by Cell Wall Deficient (CWD) bacteria of various species.
These bacteria are able to hide safely inside phagocytes (large white blood cells in the body’s immune system which are designed to engulf and digest foreign invaders) instead of being “digested” (killed) by the phagocytic cells that ingested them.
These infected white blood cells are themselves the source of the elevated 1,25-D levels in our bodies. Normally, 25-D is converted to 1,25-D only in the kidneys, where the body has distinct processes that regulate the conversion rate. White blood cells that host CWD bacteria, however, convert 25-D to 1,25-D on their own. The process is self-perpetuating, because with higher levels of 1,25-D circulating in our bodies it becomes easier for still more CWD bacteria to penetrate white blood cells.
Detection of inflammation caused by these bacteria is accomplished with two basic blood tests….the D metabolites:
1,25 dihydroxyvitamin-D and 25 hydroxyvitamin-D.
The body normally regulates the amount of 1,25-D it generates. This is a secosteroid hormone and is critical to many functions throughout the body.
But 1,25-D is also a paracrine mediator, a cytokine. The concentration in inflamed tissue builds up to many times greater than it is in the bloodstream, and the kidneys cannot regulate its level in the tissue. The kidneys do try to regulate the level in the blood, however.
An essential part of the Marshall Protocol is avoidance of foods and supplements containing vitamin D to reduce the level of 25-D which suppresses the immune system.
The aim of cutting your 25-D down is to prevent it from displacing the active metabolite from the Vitamin D Receptor, thus preventing normal immune system function.
The kidneys will try and regulate the levels of 1,25-D which reach the bloodstream. In acute Th1 disease they can’t do that, there is just too much 1,25-D being created for the kidneys to regulate it.
It may be necessary for many people, but not all, to avoid exposure to natural light and bright lights.
A key part of the protocol is the establishment of an inflammatory blockade of the hormone Angiotensin II with an Angiotensin Receptor Blocker (ARB), Benicar (olmesartan medoxomil).
The protocol also includes the introduction of carefully, selected low dose antibiotics in a pulsed schedule.
For detailed information on implementing the Marshall Protocol, see the MP Phase 1 Document.pdf